{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T11:03:11Z","timestamp":1775300591219,"version":"3.50.1"},"reference-count":189,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicines"],"abstract":"<jats:p>Background: Adverse effects of antiseizure medications (ASMs) remain one of the major causes of non-adherence. Cosmetic side effects (CSEs) are among the most commonly reported side effects of ASMs. In this context, alopecia is one of the CSEs that has a high intolerance rate leading to poor therapeutical compliance. Methods: We performed a literature review concerning alopecia as a secondary effect of ASMs. Results: There are 1656 individuals reported with ASM-induced alopecia. Valproate (983), lamotrigine (355), and carbamazepine (225) have been extensively reported. Other ASMs associated with alopecia were cenobamate (18), levetiracetam (14), topiramate (13), lacosamide (7), vigabatrin (6), phenobarbital (5), gabapentin (5), phenytoin (4), pregabalin (4), eslicarbazepine (3), brivaracetam (2), clobazam (2), perampanel (2), trimethadione (2), rufinamide (2), zonisamide (2), primidone (1), and tiagabine (1). There were no reports of oxcarbazepine and felbamate with drug-induced alopecia. Hair loss seen with ASMs was diffuse and non-scarring. Telogen effluvium was the most common cause of alopecia. A characteristic feature was the reversibility of alopecia after ASM dose adjustment. Conclusions: Alopecia should be considered one important adverse effect of ASMs. Patients reporting hair loss with ASM therapy should be further investigated, and specialist consultation is recommended.<\/jats:p>","DOI":"10.3390\/medicines10060035","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T08:37:33Z","timestamp":1686299853000},"page":"35","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Antiseizure Medication-Induced Alopecia: A Literature Review"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6179-2177","authenticated-orcid":false,"given":"Jamir","family":"Pitton Rissardo","sequence":"first","affiliation":[{"name":"Medicine Department, Federal University of Santa Maria, Santa Maria 97105-900, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8024-2354","authenticated-orcid":false,"given":"Ana Leticia","family":"Fornari Caprara","sequence":"additional","affiliation":[{"name":"Medicine Department, Federal University of Santa Maria, Santa Maria 97105-900, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maritsa","family":"Casares","sequence":"additional","affiliation":[{"name":"AdventHealth Orlando Neuroscience Institute, 615 E Princeton Street, Suite 540, Orlando, FL 32803, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holly J.","family":"Skinner","sequence":"additional","affiliation":[{"name":"AdventHealth Epilepsy at Orlando, 615 E Princeton Street, Suite 540, Orlando, FL 32803, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umair","family":"Hamid","sequence":"additional","affiliation":[{"name":"Department of Neurology, College of Medicine, University of Illinois, Peoria, IL 61605, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3189108","DOI":"10.1155\/2016\/3189108","article-title":"Antiepileptic Drug Nonadherence and Its Predictors among People with Epilepsy","volume":"2016","author":"Getnet","year":"2016","journal-title":"Behav. Neurol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1059-1311(97)80060-X","article-title":"Factors influencing compliance with antiepileptic drug regimes","volume":"6","author":"Buck","year":"1997","journal-title":"Seizure"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1535-7511.2009.01320.x","article-title":"To comply with AED therapy\u2026 what patients are not told!","volume":"9","author":"Kanner","year":"2009","journal-title":"Epilepsy Curr."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.yebeh.2014.10.021","article-title":"Cosmetic side effects of antiepileptic drugs in adults with epilepsy","volume":"42","author":"Chen","year":"2015","journal-title":"Epilepsy Behav."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S1474-4422(12)70153-9","article-title":"Adverse effects of antiepileptic drugs","volume":"11","author":"Perucca","year":"2012","journal-title":"Lancet Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.seizure.2013.11.009","article-title":"Side-effects of antiepileptic drugs: The economic burden","volume":"23","author":"Kinderen","year":"2014","journal-title":"Seizure"},{"key":"ref_7","first-page":"272","article-title":"Diagnosis and management of the hair loss patient","volume":"40","author":"Stroud","year":"1987","journal-title":"Cutis"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3109\/10401230009147085","article-title":"Hair loss in psychopharmacology","volume":"12","author":"Mercke","year":"2000","journal-title":"Ann. Clin. Psychiatry"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000526966","article-title":"Scarring versus Non-Scarring Alopecia: An Interobserver Histopathological Reproducibility Study","volume":"9","author":"Botega","year":"2023","journal-title":"Ski. Appendage Disord."},{"key":"ref_10","first-page":"145","article-title":"Drug-induced alopecia: Review of the literature","volume":"50","author":"Llau","year":"1995","journal-title":"Therapie"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/pon.1245","article-title":"Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: A literature review","volume":"17","author":"Lemieux","year":"2008","journal-title":"Psychooncology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ejon.2012.06.003","article-title":"A comparison of men and women\u2019s experiences of chemotherapy-induced alopecia","volume":"17","author":"Can","year":"2013","journal-title":"Eur. J. Oncol. Nurs."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJM199908123410706","article-title":"The biology of hair follicles","volume":"341","author":"Paus","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_14","first-page":"1601","article-title":"Analysis of apoptosis during hair follicle regression (catagen)","volume":"151","author":"Lindner","year":"1997","journal-title":"Am. J. Pathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/bjd.19461","article-title":"Exploring the human hair follicle microbiome","volume":"184","author":"Lousada","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Natarelli, N., Gahoonia, N., and Sivamani, R.K. (2023). Integrative and Mechanistic Approach to the Hair Growth Cycle and Hair Loss. J. Clin. Med., 12.","DOI":"10.3390\/jcm12030893"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Popa, A., Carsote, M., Cretoiu, D., Dumitrascu, M.C., Nistor, C.E., and Sandru, F. (2023). Study of the Thyroid Profile of Patients with Alopecia. J. Clin. Med., 12.","DOI":"10.3390\/jcm12031115"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1365-2133.1995.tb08630.x","article-title":"Ageing and hair cycles","volume":"132","author":"Courtois","year":"1995","journal-title":"Br. J. Dermatol."},{"key":"ref_19","first-page":"990","article-title":"Drug induced alopecia","volume":"143","author":"Bemt","year":"1999","journal-title":"Ned. Tijdschr. Geneeskd."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/ced.14381","article-title":"Drug-induced alopecia areata?","volume":"46","author":"Murad","year":"2021","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/ced.14982","article-title":"Anagen effluvium and the role of trichoscopy","volume":"47","author":"Starace","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e2020074","DOI":"10.5826\/dpc.1003a74","article-title":"Prevention and Treatment of Chemotherapy-Induced Alopecia","volume":"10","author":"Rossi","year":"2020","journal-title":"Dermatol. Pract. Concept."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000519817","article-title":"Psychological Aspects of Hair Disorders: Consideration for Dermatologists, Cosmetologists, Aesthetic, and Plastic Surgeons","volume":"8","author":"Moattari","year":"2022","journal-title":"Ski. Appendage Disord."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"310","DOI":"10.2165\/00002018-199410040-00005","article-title":"Drug-induced hair loss and hair growth. Incidence, management and avoidance","volume":"10","author":"Tosti","year":"1994","journal-title":"Drug Saf."},{"key":"ref_25","first-page":"5","article-title":"Chemotherapy-induced hair loss","volume":"15","year":"2010","journal-title":"Ski. Ther. Lett."},{"key":"ref_26","first-page":"1","article-title":"Telogen Effluvium: A Review","volume":"9","author":"Malkud","year":"2015","journal-title":"J. Clin. Diagn. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1046\/j.1365-4362.1999.00003.x","article-title":"Diffuse hair loss","volume":"38","author":"Sinclair","year":"1999","journal-title":"Int. J. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3109\/10401239609147756","article-title":"Alopecia and mood stabilizer therapy","volume":"8","author":"McKinney","year":"1996","journal-title":"Ann. Clin. Psychiatry"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0197-0186(00)00013-9","article-title":"Mechanisms of action of valproate: A commentatory","volume":"37","author":"Johannessen","year":"2000","journal-title":"Neurochem. Int."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"140","DOI":"10.14712\/23362936.2021.14","article-title":"Valproate-associated Movement Disorder: A Literature Review","volume":"122","author":"Rissardo","year":"2021","journal-title":"Prague Med. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1528-1157.1984.tb05636.x","article-title":"Adverse effects of valproate","volume":"25","author":"Schmidt","year":"1984","journal-title":"Epilepsia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1528-1157.1973.tb03955.x","article-title":"Dipropylacetate (D\u00e9pakine, Ergenyl) in the treatment of epilepsy","volume":"14","author":"Doose","year":"1973","journal-title":"Epilepsia"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-4362.1995.tb01556.x","article-title":"Drug-associated alopecia","volume":"34","author":"Pillans","year":"1995","journal-title":"Int. J. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1212\/WNL.48.1.182","article-title":"Safety and efficacy of divalproex sodium monotherapy in partial epilepsy: A double-blind, concentration-response design clinical trial. Depakote Monotherapy for Partial Seizures Study Group","volume":"48","author":"Beydoun","year":"1997","journal-title":"Neurology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.seizure.2019.04.003","article-title":"Risk of valproic acid-related alopecia: A systematic review and meta-analysis","volume":"69","author":"Wang","year":"2019","journal-title":"Seizure"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e2814","DOI":"10.1002\/hup.2814","article-title":"Valproate-associated hair abnormalities: Pathophysiology and management strategies","volume":"37","author":"Praharaj","year":"2022","journal-title":"Hum. Psychopharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1365-4362.1993.tb01468.x","article-title":"Telogen effluvium: An etiopathogenetic theory","volume":"32","author":"Rebora","year":"1993","journal-title":"Int. J. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejpn.2008.08.007","article-title":"The influence of valproic acid treatment on hair and serum zinc levels and serum biotinidase activity","volume":"13","author":"Yilmaz","year":"2009","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1212\/WNL.34.10.1393","article-title":"Selenium, zinc, and copper changes with valproic acid: Possible relation to drug side effects","volume":"34","author":"Hurd","year":"1984","journal-title":"Neurology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.tiv.2007.09.004","article-title":"Inhibition of human aromatase complex (CYP19) by antiepileptic drugs","volume":"22","author":"Jacobsen","year":"2008","journal-title":"Toxicol. In Vitro"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.seizure.2010.01.006","article-title":"The effect of anti epileptic drug therapy on serum 25-hydroxyvitamin D and parameters of calcium and bone metabolism--a longitudinal study","volume":"19","author":"Menon","year":"2010","journal-title":"Seizure"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF02191552","article-title":"Alopecia and mood stabilizers: Two case reports","volume":"242","author":"Uehlinger","year":"1992","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1600-0404.1982.tb03106.x","article-title":"Clinical and pharmacokinetic observations on sodium valproate\u2014A 5-year follow-up study in 100 children with epilepsy","volume":"65","author":"Henriksen","year":"1982","journal-title":"Acta Neurol. Scand."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1177\/106002809502901225","article-title":"Treatment of valproate-induced alopecia","volume":"29","author":"Fatemi","year":"1995","journal-title":"Ann. Pharmacother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.jaad.2005.11.1104","article-title":"The diagnosis and treatment of iron deficiency and its potential relationship to hair loss","volume":"54","author":"Trost","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/0883073809336118","article-title":"Serum biotinidase activity in children treated with valproic acid and carbamazepine","volume":"25","year":"2010","journal-title":"J. Child. Neurol."},{"key":"ref_47","first-page":"269","article-title":"Agomelatine may alleviate valproate induced hair loss","volume":"30","author":"Sahin","year":"2017","journal-title":"J. Psych. Neurol. Sci."},{"key":"ref_48","first-page":"1","article-title":"Sodium Valproate Induced Alopecia: A Case Series","volume":"11","author":"Thomson","year":"2017","journal-title":"J. Clin. Diagn. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"150","DOI":"10.4103\/ijt.ijt_10_18","article-title":"Valproate: It\u2019s Effects on Hair","volume":"10","author":"Kakunje","year":"2018","journal-title":"Int. J. Trichol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1528-1157.1987.tb05780.x","article-title":"Carbamazepine side effects in children and adults","volume":"28","author":"Pellock","year":"1987","journal-title":"Epilepsia"},{"key":"ref_51","first-page":"924","article-title":"Carbamazepine-induced hair loss","volume":"19","author":"Shuper","year":"1985","journal-title":"Drug Intell. Clin. Pharm."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJM199209103271104","article-title":"A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults","volume":"327","author":"Mattson","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1136\/jnnp.63.4.549","article-title":"Alopecia with carbamazepine in two patients with focal seizures","volume":"63","author":"Ikeda","year":"1997","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"532","DOI":"10.2340\/00015555-0500","article-title":"Concurrence of palmoplantar psoriasiform eruptions and hair loss during carbamazepine treatment","volume":"88","author":"Oh","year":"2008","journal-title":"Acta Derm. Venereol."},{"key":"ref_55","first-page":"392","article-title":"Overview of drugs used for epilepsy and seizures: Etiology, diagnosis, and treatment","volume":"35","author":"Goldenberg","year":"2010","journal-title":"Pharm. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Rybakowski, J.K. (2023). Mood Stabilizers of First and Second Generation. Brain Sci., 13.","DOI":"10.3390\/brainsci13050741"},{"key":"ref_57","first-page":"239","article-title":"Intravenous immunoglobulin in the treatment of lamotrigine- induced toxic epidermal necrolysis","volume":"7","author":"Shirazi","year":"2008","journal-title":"Iran. J. Allergy Asthma Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/000155550410021466","article-title":"Telogen effluvium caused by magnesium valproate and lamotrigine","volume":"85","author":"Patrizi","year":"2005","journal-title":"Acta Derm. Venereol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1176\/ajp.2006.163.8.1451","article-title":"Hair loss as a side effect of lamotrigine treatment","volume":"163","author":"Hillemacher","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/MJT.0000000000000586","article-title":"Lamotrigine Induces Hair Loss in a Patient with Treatment-Resistant Major Depressive Disorder","volume":"24","author":"Solmi","year":"2017","journal-title":"Am. J. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2165\/11536190-000000000-00000","article-title":"Alopecia in association with lamotrigine use: An analysis of individual case safety reports in a global database","volume":"33","author":"Tengstrand","year":"2010","journal-title":"Drug Saf."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.seizure.2011.04.004","article-title":"Levetiracetam monotherapy--outcomes from an epilepsy clinic","volume":"20","author":"Stephen","year":"2011","journal-title":"Seizure"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1592\/phco.21.17.1375.34432","article-title":"Levetiracetam: A novel antiepileptic drug","volume":"21","author":"Hovinga","year":"2001","journal-title":"Pharmacotherapy"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/0278-5846(95)00022-N","article-title":"Cognitive effects of a new pyrrolidine derivative (levetiracetam) in patients with epilepsy","volume":"19","author":"Neyens","year":"1995","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.seizure.2013.11.007","article-title":"Hair loss with levetiracetam in five patients with epilepsy","volume":"23","author":"Zou","year":"2014","journal-title":"Seizure"},{"key":"ref_66","first-page":"44","article-title":"Role of Zinc Supplementation in the Treatment of Levetiracetam-Induced Hair Loss: A Case Series","volume":"4","author":"Aghamollaii","year":"2017","journal-title":"J. Pharm. Care."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2165\/00003495-199346030-00007","article-title":"Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy","volume":"46","author":"Goa","year":"1993","journal-title":"Drugs"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1046\/j.0003-2409.2001.02399.x","article-title":"Gabapentin: Pharmacology and its use in pain management","volume":"57","author":"Rose","year":"2002","journal-title":"Anaesthesia"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jpainsymman.2008.09.001","article-title":"Alopecia associated with gabapentin in the treatment of neuropathic pain","volume":"37","author":"Eker","year":"2009","journal-title":"J. Pain Symptom Manag."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1177\/106002809703101020","article-title":"Alopecia associated with gabapentin: First case","volume":"31","author":"Picard","year":"1997","journal-title":"Ann. Pharmacother."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000069255","article-title":"Topiramate-induced hair loss: Case report","volume":"3","author":"Chuang","year":"2002","journal-title":"Dermatol. Psychosom."},{"key":"ref_72","first-page":"71","article-title":"Hair Loss Following The Topiramate Treatment","volume":"19","author":"Ghafoor","year":"2017","journal-title":"J. Babol. Univ. Med. Sci."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"52","DOI":"10.5334\/tohm.664","article-title":"Tremor Drugs in the Crosshairs","volume":"11","author":"Lagrand","year":"2021","journal-title":"Tremor Other Hyperkinetic Mov."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/j.1528-1157.1988.tb04237.x","article-title":"Clinical side effects of phenobarbital, primidone, phenytoin, carbamazepine, and valproate during monotherapy in children","volume":"29","author":"Herranz","year":"1988","journal-title":"Epilepsia"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"378","DOI":"10.2165\/00002018-199615060-00003","article-title":"A comparative review of the adverse effects of anticonvulsants in children with epilepsy","volume":"15","author":"Wallace","year":"1996","journal-title":"Drug Saf."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1177\/0961203318821156","article-title":"Munchausen by proxy syndrome mimicking childhood-onset systemic lupus erythematosus","volume":"28","author":"Kuhne","year":"2019","journal-title":"Lupus"},{"key":"ref_77","first-page":"929","article-title":"Phenytoin associated alopecia: Drug induced lupus","volume":"49","author":"Mangalvedhekar","year":"2001","journal-title":"J. Assoc. Physicians India"},{"key":"ref_78","first-page":"188","article-title":"Phenytoin induced alopecia & Lupus: A case report","volume":"5","author":"Neki","year":"2015","journal-title":"RGUHS J. Med. Sci."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.pathophys.2017.12.001","article-title":"Oral phenytoin protects against experimental cyclophosphamide-chemotherapy induced hair loss","volume":"25","author":"Onaolapo","year":"2018","journal-title":"Pathophysiology"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2165\/11585030-000000000-00000","article-title":"Intensive monitoring of pregabalin: Results from an observational, Web-based, prospective cohort study in the Netherlands using patients as a source of information","volume":"34","author":"Harmark","year":"2011","journal-title":"Drug Saf."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/bdrb.21175","article-title":"Developmental Toxicity Studies with Pregabalin in Rats: Significance of Alterations in Skull Bone Morphology","volume":"107","author":"Morse","year":"2016","journal-title":"Birth Defects Res. B Dev. Reprod. Toxicol."},{"key":"ref_82","first-page":"41","article-title":"Hair loss due to pregabaline: A case report","volume":"3","author":"Turgut","year":"2020","journal-title":"Med. Res. Rep."},{"key":"ref_83","first-page":"475","article-title":"DRESS syndrome induced by pregabalin in postherpetic neuralgia","volume":"68","author":"Suh","year":"2016","journal-title":"Korean J. Derm."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.phrs.2012.12.006","article-title":"Novel treatment options for epilepsy: Focus on perampanel","volume":"70","author":"Franco","year":"2013","journal-title":"Pharmacol. Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1212\/WNL.0b013e3182635735","article-title":"Adjunctive perampanel for refractory partial-onset seizures: Randomized phase III study 304","volume":"79","author":"French","year":"2012","journal-title":"Neurology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1212\/WNL.0000000000001930","article-title":"Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial","volume":"85","author":"French","year":"2015","journal-title":"Neurology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.yebeh.2018.06.033","article-title":"Efficacy and tolerability of perampanel in children and adolescents with pharmacoresistant epilepsy: The first real-world evaluation in Asian pediatric neurology clinics","volume":"85","author":"Lin","year":"2018","journal-title":"Epilepsy Behav."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1111\/epi.14520","article-title":"Perampanel in routine clinical use across Europe: Pooled, multicenter, observational data","volume":"59","author":"Rohracher","year":"2018","journal-title":"Epilepsia"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.eplepsyres.2016.08.001","article-title":"Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA study","volume":"126","author":"Villanueva","year":"2016","journal-title":"Epilepsy Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/chir.10177","article-title":"Stereostructure-activity studies on agonists at the AMPA and kainate subtypes of ionotropic glutamate receptors","volume":"15","author":"Johansen","year":"2003","journal-title":"Chirality"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"15453","DOI":"10.1038\/s41598-021-94816-y","article-title":"Glutamic acid promotes hair growth in mice","volume":"11","author":"Jara","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/08820130902896824","article-title":"Alopecia areata universalis after phenobarbital-induced anti-convulsant hypersensitivity syndrome","volume":"38","author":"Huang","year":"2009","journal-title":"Immunol. Investig."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1542\/peds.78.4.581","article-title":"Graft versus host-like illness in a child with phenobarbital hypersensitivity","volume":"78","author":"Knutsen","year":"1986","journal-title":"Pediatrics"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1345\/aph.1E042","article-title":"Anticonvulsant hypersensitivity syndrome: Lymphocyte toxicity assay for the confirmation of diagnosis and risk assessment","volume":"38","author":"Bavdekar","year":"2004","journal-title":"Ann. Pharmacother."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"174","DOI":"10.2174\/1871527319666201207205916","article-title":"Acute Phenobarbital Poisoning for the Management of Seizures in Newborns and Children; A Systematic Literature Review","volume":"20","author":"Sadeghi","year":"2021","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref_96","first-page":"51","article-title":"Hair loss-an adverse reaction to treatment with vigabatrin","volume":"22","author":"Lampl","year":"1996","journal-title":"Acta Therap."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2125.1989.tb03460.x","article-title":"Neuropathology of vigabatrin","volume":"27","author":"Graham","year":"1989","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.yebeh.2013.05.006","article-title":"Tiagabine in clinical practice: Effects on seizure control and behavior","volume":"8","author":"Vossler","year":"2013","journal-title":"Epilepsy Behav."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJM196012082632308","article-title":"Alopecia as a side effect of treatment of epilepsy with trimethadione: Report of two cases","volume":"263","author":"Holowach","year":"1960","journal-title":"N. Engl. J. Med."},{"key":"ref_100","first-page":"1","article-title":"Carbamazepine Induced Hypersensitivity Syndrome with Alopecia","volume":"45","author":"Wadhwa","year":"1997","journal-title":"J. Assoc. Physic. Ind."},{"key":"ref_101","first-page":"379","article-title":"A case of hair loss induced by carbamazepine","volume":"44","author":"Kohno","year":"2004","journal-title":"Rinsho Shinkeigaku"},{"key":"ref_102","first-page":"31","article-title":"Alopecia associated with treatment of symptomatic focal epilepsy with carbamazepine","volume":"13","author":"Zenkov","year":"2008","journal-title":"Neurol. J."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.seizure.2013.11.016","article-title":"Carbamazepine treatment of generalized tonic-clonic seizures in idiopathic generalized epilepsy","volume":"23","author":"Kenyon","year":"2014","journal-title":"Seizure"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1212\/WNL.0000000000012387","article-title":"Carbamazepine-Induced Acute Alopecia Areata","volume":"97","author":"Rathore","year":"2021","journal-title":"Neurology"},{"key":"ref_105","first-page":"40","article-title":"A Case Report-Alopecia as a Rare but Possible Side Effect of Gabapentin","volume":"20","author":"Chen","year":"2010","journal-title":"Chin. J. Pain"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.yebeh.2013.06.032","article-title":"Can zinc depletion play a role in LEV-induced hair loss? Considerations from a case study","volume":"29","author":"Calabro","year":"2013","journal-title":"Epilepsy Behav."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1055\/s-0038-1666814","article-title":"Adolescent\u2019s Hair Loss due to Levetiracetam","volume":"7","author":"Hamd","year":"2018","journal-title":"J. Pediatr. Epilepsy"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1007\/s10072-023-06633-y","article-title":"Reversible subacute hair loss induced by levetiracetam","volume":"44","author":"Missori","year":"2023","journal-title":"Neurol. Sci."},{"key":"ref_109","first-page":"350","article-title":"Prolonged Drug-Induced Hypersensitivity Syndrome\/DRESS with Alopecia Areata and Autoimmune Thyroiditis","volume":"39","author":"Krivda","year":"2022","journal-title":"Fed. Pract."},{"key":"ref_110","first-page":"141","article-title":"Unwanted effects of sodium valproate (Epilim) in the treatment of adult patients with epilepsy","volume":"1","author":"Laljee","year":"1980","journal-title":"R. Soc. Med"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1176\/ps.50.11.1500","article-title":"Divalproex-induced alopecia: A case report","volume":"50","author":"Khan","year":"1999","journal-title":"Psychiatr. Serv."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1090-3798(08)70717-7","article-title":"A case of alopecia areata associated with low dosage VPA treatment","volume":"11","author":"Cinbis","year":"2007","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/j.1528-1167.2006.00933.x","article-title":"Valproic acid-induced hair-texture changes in a white woman","volume":"48","author":"Wilting","year":"2007","journal-title":"Epilepsia"},{"key":"ref_114","first-page":"74","article-title":"Valproate-induced hair loss: What to tell patients","volume":"10","author":"Jain","year":"2011","journal-title":"Curr. Psychiatry"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4103\/0253-7613.108315","article-title":"Serum drug level-related sodium valproate-induced hair loss","volume":"45","author":"Ramakrishnappa","year":"2013","journal-title":"Indian J. Pharmacol."},{"key":"ref_116","first-page":"112","article-title":"Sodium valproate induced alopecia in a patient of epilepsy","volume":"15","author":"Panwar","year":"2016","journal-title":"J. Dent. Med. Sci."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e838","DOI":"10.4088\/JCP.17cr11469","article-title":"A Case Report of Biotin Treatment for Valproate-Induced Hair Loss","volume":"78","author":"Grootens","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"566","DOI":"10.9758\/cpn.2019.17.4.566","article-title":"Valproate Induced Hair Loss and Curly Hair in Bipolar Disorder","volume":"17","author":"Uygur","year":"2019","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s12098-020-03390-0","article-title":"Alopecia in Breastfed Infant Possibly Due to Mother Getting Valproate","volume":"88","author":"Govindan","year":"2021","journal-title":"Indian J. Pediatr."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2230.1982.tb02481.x","article-title":"Carbamazepine (\u2018Tegretol\u2019) and toxic epidermal necrolysis: Report of three cases with histopathological observations","volume":"7","author":"Breathnach","year":"1982","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(77)91154-0","article-title":"Valproate and curly hair","volume":"1","author":"Jeavons","year":"1977","journal-title":"Lancet"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"690","DOI":"10.4103\/0253-7613.169587","article-title":"Dose-dependent valproate-induced alopecia in patients with mental disorders","volume":"47","author":"Tomita","year":"2015","journal-title":"Indian J. Pharmacol."},{"key":"ref_123","first-page":"354","article-title":"Alopecia areata during treatment with zonisamide\u2014Two case reports","volume":"34","author":"Bauer","year":"2007","journal-title":"Aktuelle Neurol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.seizure.2018.07.017","article-title":"Tolerability, efficacy and retention rate of Brivaracetam in patients previously treated with Levetiracetam: A monocenter retrospective outcome analysis","volume":"61","author":"Hirsch","year":"2018","journal-title":"Seizure"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1111\/epi.17304","article-title":"Tolerability and efficacy of adjunctive brivaracetam in adults with focal seizures by concomitant antiseizure medication use: Pooled results from three phase 3 trials","volume":"63","author":"Ryvlin","year":"2022","journal-title":"Epilepsia"},{"key":"ref_126","unstructured":"Talati, R., Scholle, J.M., and Phung, O.J. (2023, May 28). Effectiveness and Safety of Antiepileptic Medications in Patients with Epilepsy [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK83942\/."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1136\/jnnp.57.6.682","article-title":"A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy","volume":"57","author":"Richens","year":"1994","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1469-8749.1995.tb11978.x","article-title":"A multicentre comparative trial of sodium valproate and carbamazepine in paediatric epilepsy","volume":"37","author":"Verity","year":"1995","journal-title":"Dev. Med. Child. Neurol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.seizure.2005.09.011","article-title":"The LAM-SAFE Study: Lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults","volume":"14","author":"Steinhoff","year":"2005","journal-title":"Seizure"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1034\/j.1600-0404.2003.00093.x","article-title":"Topiramate, carbamazepine and valproate monotherapy: Double-blind comparison in newly diagnosed epilepsy","volume":"107","author":"Privitera","year":"2003","journal-title":"Acta Neurol. Scand."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/08830738040190020901","article-title":"Topiramate, carbamazepine, and valproate monotherapy: Double-blind comparison in children with newly diagnosed epilepsy","volume":"19","author":"Wheless","year":"2004","journal-title":"J. Child Neurol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.seizure.2007.05.006","article-title":"The cognitive effects of oxcarbazepine versus carbamazepine or valproate in newly diagnosed children with partial seizures","volume":"16","author":"Donati","year":"2007","journal-title":"Seizure"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1528-1157.1987.tb03678.x","article-title":"Clobazam in therapy-resistant patients with partial epilepsy: A double-blind placebo-controlled crossover study","volume":"28","author":"Koeppen","year":"1987","journal-title":"Epilepsia"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"108671","DOI":"10.1016\/j.yebeh.2022.108671","article-title":"Evaluation of one-year effectiveness of clobazam as an add-on therapy to anticonvulsant monotherapy in participants with epilepsy having uncontrolled seizure episodes: An Indian experience","volume":"130","author":"Satishchandra","year":"2022","journal-title":"Epilepsy Behav."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"e989","DOI":"10.1212\/WNL.0000000000200792","article-title":"Long-Term Efficacy and Safety From an Open-Label Extension of Adjunctive Cenobamate in Patients with Uncontrolled Focal Seizures","volume":"99","author":"Klein","year":"2022","journal-title":"Neurology"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/epi.16525","article-title":"Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study","volume":"61","author":"Sperling","year":"2020","journal-title":"Epilepsia"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Villanueva, V., Santos-Carrasco, D., Cabezudo-Garc\u00eda, P., G\u00f3mez-Ib\u00e1\u00f1ez, A., Garc\u00e9s, M., Serrano-Castro, P., Castro-Vilanova, M.D., Sayas, D., Lopez-Gonzalez, F.J., and Rodr\u00edguez-Osorio, X. (2023). Real-world safety and effectiveness of cenobamate in patients with focal onset seizures: Outcomes from an Expanded Access Program. Epilepsia Open, epub ahead of print.","DOI":"10.1002\/epi4.12757"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/ane.12734","article-title":"Eslicarbazepine acetate as adjunctive therapy in clinical practice: ESLADOBA study","volume":"136","author":"Chaves","year":"2017","journal-title":"Acta Neurol. Scand."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40268-017-0197-5","article-title":"Eslicarbazepine Acetate: A New Improvement on a Classic Drug Family for the Treatment of Partial-Onset Seizures","volume":"17","author":"Galiana","year":"2017","journal-title":"Drugs R D"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"106561","DOI":"10.1016\/j.eplepsyres.2021.106561","article-title":"Efficacy and safety of eslicarbazepine acetate as a first or later adjunctive therapy in patients with focal seizures","volume":"171","author":"Hixson","year":"2021","journal-title":"Epilepsy Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0165-0327(98)00027-5","article-title":"Clinical experience using gabapentin adjunctively in patients with a history of mania or hypomania","volume":"49","author":"Knoll","year":"1998","journal-title":"J. Affect. Disord."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"e000467","DOI":"10.1136\/bmjpo-2019-000467","article-title":"Gabapentin for the treatment of pain manifestations in children with severe neurological impairment: A single-centre retrospective review","volume":"3","author":"Collins","year":"2019","journal-title":"BMJ Paediatr. Open"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1111\/epi.13224","article-title":"A noninterventional study evaluating the effectiveness and safety of lacosamide added to monotherapy in patients with epilepsy with partial-onset seizures in daily clinical practice: The VITOBA study","volume":"56","author":"Runge","year":"2015","journal-title":"Epilepsia"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/08830738030180021701","article-title":"Lamotrigine versus valproate monotherapy-associated weight change in adolescents with epilepsy: Results from a post hoc analysis of a randomized, double-blind clinical trial","volume":"18","author":"Biton","year":"2003","journal-title":"J. Child Neurol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/ana.21411","article-title":"Hyperandrogenism, ovulatory dysfunction, and polycystic ovary syndrome with valproate versus lamotrigine","volume":"64","author":"Morrell","year":"2008","journal-title":"Ann. Neurol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1542\/peds.80.2.165","article-title":"Psychologic and behavioral effects of antiepileptic drugs in children: A double-blind comparison between phenobarbital and valproic acid","volume":"80","author":"Vining","year":"1987","journal-title":"Pediatrics"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.yebeh.2008.12.013","article-title":"Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: First European experience","volume":"14","author":"Kluger","year":"2009","journal-title":"Epilepsy Behav."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1055\/s-0037-1599190","article-title":"Effectiveness and Tolerability of Rufinamide in Children and Young People: A Survey of Experience from the United Kingdom","volume":"6","author":"Tan","year":"2017","journal-title":"J. Pediatr. Epilepsy"},{"key":"ref_149","first-page":"48","article-title":"Weight variations in patients receiving topiramate migraine prophylaxis in a tertiary care setting","volume":"6","author":"Krymchantowski","year":"2004","journal-title":"MedGenMed"},{"key":"ref_150","first-page":"25","article-title":"Vigabatrin in pediatric patients with refractory epilepsy","volume":"48","author":"Turanli","year":"2006","journal-title":"Turk. J. Pediatr."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0920-1211(96)01013-3","article-title":"A double-blind controlled clinical trial: Oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy","volume":"26","author":"Christe","year":"1997","journal-title":"Epilepsy Res."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1136\/bmj.2.5919.584","article-title":"Sodium valproate in treatment of epilepsy","volume":"2","author":"Jeavons","year":"1974","journal-title":"Br. Med. J."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1528-1157.1977.tb04462.x","article-title":"Valproate sodium: A controlled clinical trial including monitoring of drug levels","volume":"18","author":"Gram","year":"1977","journal-title":"Epilepsia"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1600-0404.1976.tb04797.x","article-title":"Sodium valproate in the treatment of resistant epilepsy","volume":"54","author":"Hassan","year":"1976","journal-title":"Acta Neurol. Scand."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.1980.03310080019016","article-title":"Valproic acid therapy in childhood epilepsy","volume":"244","author":"Coulter","year":"1980","journal-title":"JAMA"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1136\/bmj.283.6291.577","article-title":"Effects of sodium valproate in 100 children with special reference to weight","volume":"283","author":"Egger","year":"1981","journal-title":"Br. Med. J."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/ana.410140107","article-title":"Plasma concentrations of sodium valproate: Their clinical value","volume":"14","author":"Turnbull","year":"1983","journal-title":"Ann. Neurol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0896-6974(91)90120-8","article-title":"Conversion to valproate monotheraphy in nonretarded adults with primary Generalized tonic-clonic seizures","volume":"4","author":"Spitz","year":"1991","journal-title":"J. Epilepsy"},{"key":"ref_159","first-page":"CD003196","article-title":"Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder","volume":"2001","author":"Macritchie","year":"2001","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1046\/j.1528-1157.2001.47000.x","article-title":"Low serum biotinidase activity in children with valproic acid monotherapy","volume":"42","author":"Schulpis","year":"2001","journal-title":"Epilepsia"},{"key":"ref_161","first-page":"143","article-title":"Frequency of Sodium Valproate-Induced Hair Loss and Curly Hair","volume":"4","author":"Ebrahimi","year":"2005","journal-title":"Iran. J. Pharmacol. Ther."},{"key":"ref_162","first-page":"268","article-title":"Skin findings related to chronic usage of anti-epileptic drugs","volume":"10","author":"Kocer","year":"2005","journal-title":"Neurosci. (Riyadh)"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.biopsych.2005.10.017","article-title":"Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder","volume":"59","author":"Joffe","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.yebeh.2006.02.006","article-title":"Conversion from delayed-release sodium valproate to extended-release sodium valproate: Initial results and long-term follow-up","volume":"8","author":"McCabe","year":"2006","journal-title":"Epilepsy Behav."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1468-1331.2007.02003.x","article-title":"An observational study of first-line valproate monotherapy in focal epilepsy","volume":"15","author":"Jedrzejczak","year":"2008","journal-title":"Eur. J. Neurol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1177\/0883073811409227","article-title":"The influence of valproic acid and carbamazepine treatment on serum biotin and zinc levels and on biotinidase activity","volume":"26","year":"2011","journal-title":"J. Child Neurol."},{"key":"ref_167","first-page":"57","article-title":"Analysis of 59 cases of adverse drug reactions induced by valproate sodium","volume":"39","author":"Han","year":"2015","journal-title":"Chin. Hosp. Pharm. J."},{"key":"ref_168","first-page":"28","article-title":"Prospective Observational Study of Sodium Valproate in Seizure Control and Associated Adverse Drug Reactions in Pediatric Population","volume":"14","author":"Kompally","year":"2015","journal-title":"J. Dent. Med. Sci."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/dmcn.12737","article-title":"Valproate-induced enuresis: A prospective study","volume":"57","author":"Yamak","year":"2015","journal-title":"Dev. Med. Child Neurol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.eurpsy.2018.08.003","article-title":"Severe hair loss associated with psychotropic drugs in psychiatric inpatients-Data from an observational pharmacovigilance program in German-speaking countries","volume":"54","author":"Druschky","year":"2018","journal-title":"Eur. Psychiatry"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1055\/a-2018-4946","article-title":"The Role of Mood Stabilizers in Children and Adolescents with Anorexia Nervosa: A 1-year Follow-Up, Propensity Score-Matched Study","volume":"56","author":"Pruccoli","year":"2023","journal-title":"Pharmacopsychiatry"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/17425255.2022.2075342","article-title":"Individualizing doses of antiepileptic drugs","volume":"18","author":"Liparoti","year":"2022","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_173","first-page":"e8320","article-title":"Telogen Effluvium: A Review of the Literature","volume":"12","author":"Asghar","year":"2020","journal-title":"Cureus"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jdermsci.2021.01.007","article-title":"Telogen Effluvium\u2014A review of the science and current obstacles","volume":"101","author":"Yin","year":"2021","journal-title":"J. Dermatol. Sci."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"141","DOI":"10.5021\/ad.2020.32.2.141","article-title":"Analysis of Microscopic Examination of Pulled Out Hair in Telogen Effluvium Patients","volume":"32","author":"Park","year":"2020","journal-title":"Ann. Dermatol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jaad.2016.10.002","article-title":"Hair pull test: Evidence-based update and revision of guidelines","volume":"76","author":"McDonald","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/jocd.12559","article-title":"NonScarring Diffuse Hair Loss in Women: A Clinico-Etiological Study from tertiary care center in North-West India","volume":"18","author":"Poonia","year":"2019","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"591","DOI":"10.4103\/0378-6323.116731","article-title":"Telogen effluvium","volume":"79","author":"Grover","year":"2013","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1046\/j.1365-2230.2002.01080.x","article-title":"Telogen effluvium","volume":"27","author":"Harrison","year":"2002","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"604","DOI":"10.4103\/0378-6323.116728","article-title":"Anagen effluvium","volume":"79","author":"Kanwar","year":"2013","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Liyanage, D., and Sinclair, R. (2016). Telogen Effluvium. Cosmetics, 3.","DOI":"10.3390\/cosmetics3020013"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"108","DOI":"10.4103\/0974-7753.58553","article-title":"Hair evaluation methods: Merits and demerits","volume":"1","author":"Dhurat","year":"2009","journal-title":"Int. J. Trichol."},{"key":"ref_183","first-page":"93","article-title":"Common hair loss disorders","volume":"68","author":"Springer","year":"2003","journal-title":"Am. Fam. Physician"},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Hoffmann, A., Wa\u015bkiel-Burnat, A., \u017b\u00f3\u0142kiewicz, J., Blicharz, L., Rakowska, A., Goldust, M., Olszewska, M., and Rudnicka, L. (2021). Pili Torti: A Feature of Numerous Congenital and Acquired Conditions. J. Clin. Med., 10.","DOI":"10.3390\/jcm10173901"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s13555-018-0278-6","article-title":"The Role of Vitamins and Minerals in Hair Loss: A Review","volume":"9","author":"Almohanna","year":"2019","journal-title":"Dermatol. Ther."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0022-3476(05)80334-8","article-title":"Clinical response of alopecia, trichorrhexis nodosa, and dry, scaly skin to zinc supplementation","volume":"121","author":"Slonim","year":"1992","journal-title":"J. Pediatr."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/0006-3223(92)90243-S","article-title":"Effects of long-term anticonvulsant therapy on copper, zinc, and magnesium in hair and serum of epileptics","volume":"31","author":"Suzuki","year":"1992","journal-title":"Biol. Psychiatry"},{"key":"ref_188","first-page":"61","article-title":"Effect of anti-epileptic drugs on serum zinc and copper concentrations in epileptic patients","volume":"31","author":"Kuzuya","year":"1993","journal-title":"Int. J. Clin. Pharmacol. Ther. Toxicol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.seizure.2021.05.010","article-title":"Cosmetic adverse effects of antiseizure medications; A systematic review","volume":"91","author":"Rostaminejad","year":"2021","journal-title":"Seizure"}],"container-title":["Medicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2305-6320\/10\/6\/35\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:51:49Z","timestamp":1760125909000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2305-6320\/10\/6\/35"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,9]]},"references-count":189,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["medicines10060035"],"URL":"https:\/\/doi.org\/10.3390\/medicines10060035","relation":{},"ISSN":["2305-6320"],"issn-type":[{"value":"2305-6320","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,9]]}}}